

etro studies
HICKORY

Key eligibility criteria

- 18–80 years of age (inclusive)
 - Moderately to severely active ulcerative colitis
 - Refractory to or intolerant of **one or two** of the following TNF inhibitors within the previous 5 years as defined below:
 - Signs and symptoms of persistently active disease despite a history of at least one induction regimen of the following agents:
 - Infliximab: 5 mg/kg IV, two doses
 - Adalimumab: 160 mg SC dose followed by 80 mg dose
 - Golimumab: 200 mg SC dose followed by 100 mg dose
 - or**
 - Recurrence of symptoms during scheduled maintenance dosing following prior clinical benefit (discontinuation despite clinical benefit does not qualify)
 - or**
 - History (within previous 5 years) of intolerance of at least **one or two** TNF inhibitors (including but not limited to infusion-related reaction, demyelination, congestive heart failure, infection).
- Evidence of UC extending a minimum of 20 cm from the anal verge
 - No past or present ileostomy or colostomy
 - No diagnosis of Crohn's disease.

Please consider inviting patients who fulfill the above criteria to screen for the HICKORY Study.

Refer to the Study Protocol for full eligibility criteria prior to patient enrollment.